<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, April 13, 2018 (HealthDay News) — Supplementation with n-3 fatty acids is not associated with significant benefit in dry eye disease, according to a study published online April 13 in the New England Journal of Medicine<\/i> to coincide with the annual meeting of the American Society of Cataract and Refractive Surgery, held from April 13 to 17 in Washington, D.C.<\/p>\n
Penny A. Asbell, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomized patients with moderate-to-severe dry eye disease to receive a daily oral dose of 3,000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids (329 patients) or an olive oil placebo (170 patients).<\/p>\n
The researchers found observed no significant difference between the active supplement and placebo groups in the mean change in Ocular Surface Disease Index score (\u221213.9 and \u221212.5 points, respectively; after imputation of missing data, mean difference in change, \u22121.9 points; 95 percent confidence interval, \u22125.0 to 1.1; P = 0.21). Across prespecified subgroups the result was consistent. There were also no significant between-group differences in the mean changes from baseline in the conjunctival staining score, corneal staining score, tear break-up time, and results on Schirmer’s test.<\/p>\n
“Among patients with dry eye disease, those who were randomly assigned to receive supplements containing 3,000 mg of n-3 fatty acids for 12 months did not have significantly better outcomes than those who were assigned to receive placebo,” the authors write.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n